Literature DB >> 3974999

Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes.

G Jarus, M Blumenkranz, E Hernandez, N Sossi.   

Abstract

The ocular pharmacokinetics of 5-fluorouracil (5-FU) after intravitreal administration in the rabbit are described for the first time. Following a 1 mg intravitreal injection of C-14 labeled 5-FU in the phakic nonvitrectomized eye, a peak level of 664 micrograms/ml is achieved which declines to 7.8 micrograms/ml at 24 hours. For the aphakic vitrectomized eye comparable values are 669 micrograms/ml at 0.1 hour and 0.21 micrograms/ml at 24 hours. 5-FU is cleared more than two times more rapidly in aphakic vitrectomized eyes than normal eyes during the first 12 hours following injection. Following this, when the actual concentrations are relatively low, the rate of clearance appears relatively similar for both groups of eyes. Although it is difficult to extrapolate from previous in vitro results, potentially therapeutic vitreous concentrations are present in normal rabbit eyes for up to 72 hours following a single intravitreal injection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3974999     DOI: 10.1016/s0161-6420(85)34063-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

1.  Prediction of the vitreal half-life of small molecular drug-like compounds.

Authors:  Heidi Kidron; Eva M Del Amo; Kati-Sisko Vellonen; Arto Urtti
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

2.  Intravitreal crystalline drug delivery for intraocular proliferation diseases.

Authors:  Lingyun Cheng; Karl Hostetler; Nadya Valiaeva; Ajay Tammewar; William R Freeman; James Beadle; Dirk-Uwe Bartsch; Kathy Aldern; Iryna Falkenstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-20       Impact factor: 4.799

3.  Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo.

Authors:  Haihua Zheng; Zhimin Wang; Peijuan Wang; Yaqin Liu; Zhaoxin Jiang; Qianying Gao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-27       Impact factor: 3.117

Review 4.  The clinical applications of fluorouracil in ophthalmic practice.

Authors:  Lekha M Abraham; Dinesh Selva; Robert Casson; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  [Pharmacokinetics of intravitreally administered VEGF inhibitors].

Authors:  T U Krohne; F G Holz; C H Meyer
Journal:  Ophthalmologe       Date:  2014-02       Impact factor: 1.059

6.  Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases.

Authors:  G W Blankenship
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

7.  Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.

Authors:  Jeeyun Ahn; Hyuncheol Kim; Se Joon Woo; Ji Hyun Park; Sunyoung Park; Duck Jin Hwang; Kyu Hyung Park
Journal:  J Ocul Pharmacol Ther       Date:  2013-06-04       Impact factor: 2.671

8.  Long-term efficacy and duration of action of dexamethasone implant, in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema.

Authors:  George G Bastakis; Dimitris Dimopoulos; Anastasios Stavrakakis; George Pappas
Journal:  Eye (Lond)       Date:  2018-10-09       Impact factor: 3.775

9.  Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema.

Authors:  Sadık Görkem Çevik; Sami Yılmaz; Mediha Tok Çevik; Fatma Düriye Akalp; Remzi Avcı
Journal:  J Ophthalmol       Date:  2018-04-22       Impact factor: 1.909

10.  A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation.

Authors:  Mei Chen; Jiangping Hou; Guilin Tan; Peng Xie; William R Freeman; James R Beadle; Karl Y Hostetler; Lingyun Cheng
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.